Engineered Stem Cell Vesicles Reverse Sinoatrial Node Fibrosis in Aging Heart Models

Sinus node dysfunction is one of the most prevalent arrhythmia syndromes in aging populations, responsible for hundreds of thousands of pacemaker implantations annually. The devices address symptoms but do not halt disease progression—specifically the progressive fibrosis and loss of functional pacemaker cells in the sinoatrial node (SAN). Regenerative alternatives such as gene therapy and cell transplantation have shown promise but face barriers including tumorigenicity risk, poor cell survival, and limited tissue targeting. This study addresses these challenges with a bioengineered nanotherapeutic platform.

The research team derived small extracellular vesicles (sEVs) from U2-hiPSC cultures using sequential gradient centrifugation, size-exclusion chromatography, and ultrafiltration, yielding particles of approximately 91.5 nm carrying canonical sEV markers (CD9, CD63, TSG101, Alix). Platelet membrane vesicles (PMVs) were separately prepared from rat whole blood via freeze-thaw lysis and extrusion. The two were fused by co-extrusion through 400–200 nm polycarbonate membranes at an optimized 3:1 PMV-to-i-sEV mass ratio, determined by minimizing FRET efficiency (lowest at 41.52%). The resulting PM@i-sEVs (~206 nm) retained platelet surface proteins GPVI, CD42b, and CD47, as well as hiPSC-sEV markers Alix and CD9, confirmed by Western blot and co-localization fluorescence microscopy (Pearson coefficient 0.84).

A rat SND model was established by combining sodium hydroxide permeation with ischemia-reperfusion injury (SH-IR) of the SAN region. Intravenously administered PM@i-sEVs showed 3.1-fold greater accumulation in the SAN compared to unmodified i-sEVs, as visualized by near-infrared fluorescence imaging. Functionally, treated animals demonstrated significant restoration of heart rate and intrinsic pacemaker activity. Histological analysis revealed a 63% reduction in collagen deposition in the SAN. At the molecular level, PM@i-sEV treatment upregulated the pacemaker ion channel genes HCN4 and SCN5A, suppressed fibroblast activation markers, and reduced oxidative stress markers in cardiomyocytes.

Mechanistically, the GPVI–collagen axis appears central to targeted homing: the exposed collagen in ischemic SAN tissue acts as a docking site for platelet membrane proteins on the vesicle surface. CD47 signaling confers immune evasion, with pharmacokinetic data showing higher residual PM@i-sEV concentrations in serum at 24 and 48 hours post-injection versus unmodified vesicles. Neither PMVs nor PM@i-sEVs induced platelet aggregation or hemolysis in vitro, supporting a favorable safety profile.

This work establishes proof-of-concept for a cell-free, targeted nanotherapeutic approach to SND—one that could complement or eventually reduce reliance on electronic pacemakers. The dual-function platelet membrane coating strategy (injury homing + immune evasion) is modular and potentially transferable to other fibrotic cardiac conditions. However, translation will require validation in large-animal models, assessment of long-term efficacy and safety, clarification of the active cargo (specific miRNAs or proteins) driving repair, and resolution of manufacturing scalability challenges.